Results 61 to 70 of about 937 (121)

Allopurinol Versus Febuxostat Use and the Risk of Cardiovascular Disease in People With Chronic Kidney Disease: A New-User Active Comparator Cohort Study. [PDF]

Nephrology (Carlton)
Inoue R, Yamaguchi S, Okada A, Yamauchi T, Kadowaki T, Nangaku M.   +5 more
europepmc   +1 more source

Antihypertensive drugs for hyperuricemia in patients with hypertension: a systematic review and network meta-analysis of Chinese trials. [PDF]

BMC Cardiovasc Disord
Wu J, Di H, Zhang Y, Zeng X.
europepmc   +1 more source

Safety, Tolerability, and Efficacy of Shorter Infusion Durations of Pegloticase Administered to Patients With Uncontrolled Gout Receiving Methotrexate: AGILE Trial. [PDF]

J Clin Rheumatol
Troum OM, Botson JK, Fang F, Mohammad AS, Verma S, LaMoreaux B, LaMoreaux B.   +6 more
europepmc   +1 more source

Structural Characterization and Anti-Gout Activity of a Novel Acidic <i>Sanghuangporus vaninii</i> Polysaccharide. [PDF]

Molecules
Zhang X, An S, Zhou L, Chen C, Yang X.
europepmc   +1 more source

A real-world retrospective cohort study comparing brand-name febuxostat (feburic) and generic febuxostat (feuri). [PDF]

Sci Prog
Tsai SF, Wu MJ, Chen CH.
europepmc   +1 more source

Comparative risk of retinal microvascular disorders in patients with gout initiating febuxostat versus allopurinol: a population-based cohort study. [PDF]

Sci Rep
Kim MJ, Pyo JY, Choi SR, Shin A, Choung H, Ha YJ, Lee YJ, Lee EB, Kang EH.   +8 more
europepmc   +1 more source

Clinical Practice Consensus Statement 2025: Management of Hyperuricemia and Gout in Adolescents. [PDF]

Int J Rheum Dis
Li C, Lu J, Lyu Z, Chen H, Su B, Ban B, Mao J, Liu P, Cheng Z, Zhu J, Wan N, Chen X, Gong C, Ye P, Sun M, Sun W, Zhang H, Yin H, Jiang X, Wang Q, Chen Y, Lin HY, Mi J, Zhao J.   +23 more
europepmc   +1 more source

Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China. [PDF]

Arthritis Rheumatol
Sun J, Wang Y, Cheng Y, Guo D, Hu J, Liu D, Gao Z, Li C, Lu Y, Kong X, Liu Y, Jiang Z, Yi B, Zhang H, Xu B, Yu S, Kokan R, Ishikawa K, Kawakatsu M, Zhang Z.   +19 more
europepmc   +1 more source

Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase. [PDF]

Rheumatology (Oxford)
Troum OM, Duong M, Obermeyer K, Padnick-Silver L, LaMoreaux B.   +4 more
europepmc   +1 more source

Association Between HLA-B5801 Positivity and Patient Characteristics and Clinical Outcomes in Gout. [PDF]

In Vivo
Ahn SS, Kim JA, Bae K.
europepmc   +1 more source